387 related articles for article (PubMed ID: 27539855)
1. The MET/Vascular Endothelial Growth Factor Receptor (VEGFR)-targeted Tyrosine Kinase Inhibitor Also Attenuates FMS-dependent Osteoclast Differentiation and Bone Destruction Induced by Prostate Cancer.
Watanabe K; Hirata M; Tominari T; Matsumoto C; Fujita H; Yonekura K; Murphy G; Nagase H; Miyaura C; Inada M
J Biol Chem; 2016 Sep; 291(40):20891-20899. PubMed ID: 27539855
[TBL] [Abstract][Full Text] [Related]
2. High Potency VEGFRs/MET/FMS Triple Blockade by TAS-115 Concomitantly Suppresses Tumor Progression and Bone Destruction in Tumor-Induced Bone Disease Model with Lung Carcinoma Cells.
Fujita H; Gomori A; Fujioka Y; Kataoka Y; Tanaka K; Hashimoto A; Suzuki T; Ito K; Haruma T; Yamamoto-Yokoi H; Harada N; Sakuragi M; Oda N; Matsuo K; Inada M; Yonekura K
PLoS One; 2016; 11(10):e0164830. PubMed ID: 27736957
[TBL] [Abstract][Full Text] [Related]
3. A c-fms tyrosine kinase inhibitor, Ki20227, suppresses osteoclast differentiation and osteolytic bone destruction in a bone metastasis model.
Ohno H; Kubo K; Murooka H; Kobayashi Y; Nishitoba T; Shibuya M; Yoneda T; Isoe T
Mol Cancer Ther; 2006 Nov; 5(11):2634-43. PubMed ID: 17121910
[TBL] [Abstract][Full Text] [Related]
4. Specific targeting of PKCδ suppresses osteoclast differentiation by accelerating proteolysis of membrane-bound macrophage colony-stimulating factor receptor.
Kim MY; Lee K; Shin HI; Jeong D
Sci Rep; 2019 May; 9(1):7044. PubMed ID: 31065073
[TBL] [Abstract][Full Text] [Related]
5. The novel VEGF receptor/MET-targeted kinase inhibitor TAS-115 has marked in vivo antitumor properties and a favorable tolerability profile.
Fujita H; Miyadera K; Kato M; Fujioka Y; Ochiiwa H; Huang J; Ito K; Aoyagi Y; Takenaka T; Suzuki T; Ito S; Hashimoto A; Suefuji T; Egami K; Kazuno H; Suda Y; Nishio K; Yonekura K
Mol Cancer Ther; 2013 Dec; 12(12):2685-96. PubMed ID: 24140932
[TBL] [Abstract][Full Text] [Related]
6. Blocking of the Ubiquitin-Proteasome System Prevents Inflammation-Induced Bone Loss by Accelerating M-CSF Receptor c-Fms Degradation in Osteoclast Differentiation.
Lee K; Kim MY; Ahn H; Kim HS; Shin HI; Jeong D
Int J Mol Sci; 2017 Sep; 18(10):. PubMed ID: 28946669
[TBL] [Abstract][Full Text] [Related]
7. Dual targeting c-met and VEGFR2 in osteoblasts suppresses growth and osteolysis of prostate cancer bone metastasis.
Lee C; Whang YM; Campbell P; Mulcrone PL; Elefteriou F; Cho SW; Park SI
Cancer Lett; 2018 Feb; 414():205-213. PubMed ID: 29174801
[TBL] [Abstract][Full Text] [Related]
8. The Tyrosine Kinase Inhibitor TAS-115 Attenuates Bleomycin-induced Lung Fibrosis in Mice.
Koyama K; Goto H; Morizumi S; Kagawa K; Nishimura H; Sato S; Kawano H; Toyoda Y; Ogawa H; Homma S; Nishioka Y
Am J Respir Cell Mol Biol; 2019 Apr; 60(4):478-487. PubMed ID: 30540913
[TBL] [Abstract][Full Text] [Related]
9. Imatinib mesylate suppresses bone metastases of breast cancer by inhibiting osteoclasts through the blockade of c-Fms signals.
Hiraga T; Nakamura H
Int J Cancer; 2009 Jan; 124(1):215-22. PubMed ID: 18814279
[TBL] [Abstract][Full Text] [Related]
10. Reduced c-Met expression by an adenovirus expressing a c-Met ribozyme inhibits tumorigenic growth and lymph node metastases of PC3-LN4 prostate tumor cells in an orthotopic nude mouse model.
Kim SJ; Johnson M; Koterba K; Herynk MH; Uehara H; Gallick GE
Clin Cancer Res; 2003 Nov; 9(14):5161-70. PubMed ID: 14613995
[TBL] [Abstract][Full Text] [Related]
11. TAS-115 inhibits PDGFRα/AXL/FLT-3 signaling and suppresses lung metastasis of osteosarcoma.
Yasuda N; Takenaka S; Nakai S; Nakai T; Yamada S; Imura Y; Outani H; Hamada K; Yoshikawa H; Naka N
FEBS Open Bio; 2020 May; 10(5):767-779. PubMed ID: 32128992
[TBL] [Abstract][Full Text] [Related]
12. JNJ-28312141, a novel orally active colony-stimulating factor-1 receptor/FMS-related receptor tyrosine kinase-3 receptor tyrosine kinase inhibitor with potential utility in solid tumors, bone metastases, and acute myeloid leukemia.
Manthey CL; Johnson DL; Illig CR; Tuman RW; Zhou Z; Baker JF; Chaikin MA; Donatelli RR; Franks CF; Zeng L; Crysler C; Chen Y; Yurkow EJ; Boczon L; Meegalla SK; Wilson KJ; Wall MJ; Chen J; Ballentine SK; Ott H; Baumann C; Lawrence D; Tomczuk BE; Molloy CJ
Mol Cancer Ther; 2009 Nov; 8(11):3151-61. PubMed ID: 19887542
[TBL] [Abstract][Full Text] [Related]
13. Low-density lipoprotein receptor deficiency causes impaired osteoclastogenesis and increased bone mass in mice because of defect in osteoclastic cell-cell fusion.
Okayasu M; Nakayachi M; Hayashida C; Ito J; Kaneda T; Masuhara M; Suda N; Sato T; Hakeda Y
J Biol Chem; 2012 Jun; 287(23):19229-41. PubMed ID: 22500026
[TBL] [Abstract][Full Text] [Related]
14. c-Fms signaling mediates neurofibromatosis Type-1 osteoclast gain-in-functions.
He Y; Rhodes SD; Chen S; Wu X; Yuan J; Yang X; Jiang L; Li X; Takahashi N; Xu M; Mohammad KS; Guise TA; Yang FC
PLoS One; 2012; 7(11):e46900. PubMed ID: 23144792
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases.
Qian F; Engst S; Yamaguchi K; Yu P; Won KA; Mock L; Lou T; Tan J; Li C; Tam D; Lougheed J; Yakes FM; Bentzien F; Xu W; Zaks T; Wooster R; Greshock J; Joly AH
Cancer Res; 2009 Oct; 69(20):8009-16. PubMed ID: 19808973
[TBL] [Abstract][Full Text] [Related]
16. Caffeic acid 3,4-dihydroxy-phenethyl ester suppresses receptor activator of NF-κB ligand–induced osteoclastogenesis and prevents ovariectomy-induced bone loss through inhibition of mitogen-activated protein kinase/activator protein 1 and Ca2+–nuclear factor of activated T-cells cytoplasmic 1 signaling pathways.
Wu X; Li Z; Yang Z; Zheng C; Jing J; Chen Y; Ye X; Lian X; Qiu W; Yang F; Tang J; Xiao J; Liu M; Luo J
J Bone Miner Res; 2012 Jun; 27(6):1298-1308. PubMed ID: 22337253
[TBL] [Abstract][Full Text] [Related]
17. The tyrosine kinase inhibitor GNF-2 suppresses osteoclast formation and activity.
Kim HJ; Yoon HJ; Choi JY; Lee IK; Kim SY
J Leukoc Biol; 2014 Feb; 95(2):337-45. PubMed ID: 24130113
[TBL] [Abstract][Full Text] [Related]
18. Interleukin-34 is expressed by giant cell tumours of bone and plays a key role in RANKL-induced osteoclastogenesis.
Baud'huin M; Renault R; Charrier C; Riet A; Moreau A; Brion R; Gouin F; Duplomb L; Heymann D
J Pathol; 2010 May; 221(1):77-86. PubMed ID: 20191615
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of TAS-115 via c-MET and PDGFRα signal inhibition for synovial sarcoma.
Yamada S; Imura Y; Nakai T; Nakai S; Yasuda N; Kaneko K; Outani H; Takenaka S; Hamada K; Myoui A; Araki N; Ueda T; Itoh K; Yoshikawa H; Naka N
BMC Cancer; 2017 May; 17(1):334. PubMed ID: 28511645
[TBL] [Abstract][Full Text] [Related]
20. VEGF, FLT3 ligand, PlGF and HGF can substitute for M-CSF to induce human osteoclast formation: implications for giant cell tumour pathobiology.
Taylor RM; Kashima TG; Knowles HJ; Athanasou NA
Lab Invest; 2012 Oct; 92(10):1398-406. PubMed ID: 22906984
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
